GlobeNewswire (May 17, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (May 10, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
-
-
GlobeNewswire (Mar 15, 2013)
-
GlobeNewswire (Mar 8, 2013)
-
GlobeNewswire (Mar 5, 2013)
-
GlobeNewswire (Feb 14, 2013)
-
-
GlobeNewswire (Jan 22, 2013)
-
-
5 Biotech Winners From Last Week With High Short RatiosHeisenberg Principle • Mon, Dec 24, 2012 -
-
-
GlobeNewswire (Nov 29, 2012)
-
GlobeNewswire (Nov 28, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
FDA Response To Progenics' Supplemental NDA Application LoomsBrian L. Wilson • Fri, Apr 20, 2012
-
Progenics Should Outperform The Market In The Short TermBinaryLeverage • Wed, Feb 15, 2012 -
Progenics Pharmaceuticals JumpedM. E. Garza • Thu, Dec 1, 2011 -
-
-
-
-
5 Biotech Winners From Last Week With High Short RatiosHeisenberg Principle • Mon, Dec 24, 2012
-
-
-
-
-
-
-
-
2 Pharma Stocks To Consider In The Wake Of An FDA RejectionMatt Schilling • Mon, Jul 30, 2012
-
Dendreon Reports Q2 Earnings On July 30Vytautas Drumelis • Thu, Jul 26, 2012 -
-
-
-
-
-
-
-
GlobeNewswire (May 17, 2013)
-
GlobeNewswire (May 10, 2013)
-
GlobeNewswire (May 6, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
at CNBC.com (Apr 1, 2013)
-
GlobeNewswire (Mar 15, 2013)
-
GlobeNewswire (Mar 8, 2013)
-
GlobeNewswire (Mar 5, 2013)
-
GlobeNewswire (Feb 14, 2013)
-
GlobeNewswire (Jan 22, 2013)
-
GlobeNewswire (Nov 29, 2012)
-
GlobeNewswire (Nov 28, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 6, 2012)
-
GlobeNewswire (Nov 2, 2012)
-
GlobeNewswire (Sep 28, 2012)
-
GlobeNewswire (Sep 20, 2012)
-
GlobeNewswire (Aug 30, 2012)
-
at CNBC.com (Aug 9, 2012)
-
GlobeNewswire (Aug 9, 2012)
PGNX vs. ETF Alternatives
Company Description
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Our principal programs are directed toward... More
